Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

Atara Biotherapeutics is halving its headcount as it navigates the fallout from the FDA’s move to halt trials of the ...

A one-time injection of a novel gene therapy was able to save mice and a newborn calf from succumbing to maple syrup urine ...

Up to 60 new life sciences companies are set to benefit from 1.6 billion euros ($1.68 billion) that Sofinnova Partners has ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

The KidneyVault is more than a simple ice chest. It pumps a cooled, specialized solution through the organ to help preserve ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Boston Scientific is diving into the field of renal denervation, with a $540 million deal for SoniVie and its ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Neumora halted one trial of its depression drug navacaprant and paused a pair of late-stage studies as it tries to learn from ...